Full text
Earnings transcript
Read the complete earnings call transcript.
6869
6869.T
Sysmex Corporation
$1939
-26
(-1.32%)
| Exchange: | JPX |
| Market Cap: | 1.167T |
| Shares Outstanding: | 626.716M |
Delayed data
About The Company
| Sector: | HealthcareView sector performance | |||||
| Industry: | Medical – SpecialtiesView industry performance | |||||
| CEO: | Hisashi Ietsugu | |||||
| Full Time Employees: | 10861 | |||||
| Address: |
| |||||
| Website: | https://www.sysmex.co.jp |
Sysmex Corporation, headquartered in Kobe, Japan, and established in 1968 (originally known as TOA Medical Electronics Co., Ltd. until its rebranding in October 1998), specializes in the development, manufacturing, and global distribution of advanced diagnostic instrumentation, chemical reagents, and associated software. Its comprehensive product portfolio addresses various diagnostic needs. In hematology, it offers instruments for both three-part and five-part white blood cell differentiation, alongside efficient transport systems designed for high-volume laboratory testing. For urinalysis, the company provides systems capable of analyzing urine formed sediment. Its offerings extend to automated immunochemistry systems, which are adept at performing assays with minute sample quantities, complemented by reagents for detecting infectious diseases and tumor markers. Sysmex also manufactures flow cytometers, crucial for the analysis involved in diagnosing conditions such as leukemia, malignant lymphoma, and HIV/AIDS. Beyond these core areas, the company is deeply involved in oncology diagnostics, developing systems for detecting cancer lymph node metastasis and cancer genome profiling, as well as offering cytogenetic testing and specialized lab assay services. Sysmex also contributes to digital medicine through the development and sale of software for diagnostic information systems, alongside the creation, operation, and maintenance of IT solutions, platforms, and applications in this field. Its activities further encompass the development and sale of nucleic acid analogs, the full lifecycle management (marketing, development, design, manufacture, sale, and after-sales support) of medical robots, and the distribution and post-sales support for medical devices and reagents used in biotechnology, medical technology, and molecular cell analysis. Sysmex serves a diverse client base, including national, public, and private hospitals, universities, research institutes, and other medical facilities. With a robust international presence, the company exports its products to approximately 190 countries worldwide. Demonstrating its commitment to innovation, Sysmex Corporation maintains a strategic alliance with QIAGEN N.V. for the collaborative development and commercialization of cancer companion diagnostics utilizing Plasma-Safe-SeqS technology.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Revenue | 461,510,000 | 508,643,000 | 500,006,000 |
| Gross Profit | 242,497,000 | 271,978,000 | 255,682,000 |
| EBITDA | 112,820,000 | 121,249,000 | 99,847,000 |
| Operating Income | 77,297,000 | 89,675,000 | 62,169,000 |
| Net Income | 49,639,000 | 53,669,000 | 35,456,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Total Assets | 618,920,000 | 665,268,000 | 707,532,000 |
| Total Liabilities | 186,020,000 | 200,731,000 | 201,852,000 |
| Total Stockholders Equity | 432,046,000 | 463,776,000 | 505,001,000 |
| Total Debt | 55,339,000 | 64,735,000 | 70,481,000 |
| Cash and Cash Equivalents | 75,507,000 | 89,570,000 | 84,117,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2024 | 2025 | 2026 |
|---|---|---|---|
| Operating Cash Flow | 63,905,000 | 88,246,000 | 73,848,000 |
| Capital Expenditure | -25,610,000 | -29,226,000 | -32,904,000 |
| Free Cash Flow | 38,295,000 | 59,020,000 | 40,944,000 |
| Net Income | 49,639,000 | 53,669,000 | 35,456,000 |
| Net Change in Cash | 6,047,000 | 14,063,000 | -5,453,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2031 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 640,683,554.670 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 714,700,014.558 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 676,027,750 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 136,911,352.152 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 151,712,842.129 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 143,979,334.054 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 66,242,282.433 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 76,358,335.722 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 71,072,882.709 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 185,537,533.153 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 206,972,188.811 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 195,772,968.049 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 114.040 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 122.520 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 106.290 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 5 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 6 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MarketSnap estimates 6869.T intrinsic value between $9.55 – $10.61 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
Common questions about 6869.T valuation
Is Sysmex Corporation (6869.T) overvalued or undervalued right now?
MarketSnap estimates intrinsic value for Sysmex Corporation (6869.T) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is 6869.T a buy, hold, or sell for long-term investors?
MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether 6869.T trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is 6869.T’s P/E ratio?
You can see 6869.T’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for 6869.T?
MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is 6869.T a good long-term investment?
Whether 6869.T fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
6869.T
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
-1.32
Trading Metrics:
| Open: | 2018 | Previous Close: | 1965 | |
| Day Low: | 1937.5 | Day High: | 2025 | |
| Year Low: | 1246 | Year High: | 2025 | |
| Price Avg 50: | 1884.11 | Price Avg 200: | 1568.91 | |
| Volume: | 3.177M | Average Volume: | 2.988M |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
